cl 387785 and erlotinib

cl 387785 has been researched along with erlotinib in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Althaus, IW; Amato, DM; Bridges, AJ; Denny, WA; Elliott, WL; Ellis, PA; Fry, DW; Gonzales, AJ; Han, HK; Harvey, PJ; Klutchko, SR; Meade, MA; Nelson, JM; Pace, G; Roberts, BJ; Sherwood, V; Showalter, HD; Smaill, JB; Tran, TP; Winters, RT; Zhou, H1
Archibald, H; Dowell, L; Drew, L; Erlander, MG; Gray, NS; Greninger, P; Haber, DA; Hanke, JH; Iafrate, AJ; Lamb, J; Lee, D; Ma, XJ; Maheswaran, S; McDermott, U; Montagut, C; Njauw, CN; Raudales, R; Rothenberg, SM; Settleman, J; Sharma, SV; Sordella, R; Supko, JG; Tam, A; Tsao, H; Ulkus, LE1
Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Chorley, CG; Chuaqui, C; Colclough, N; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Grist, M; Hill, GB; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Ward, RA; Waring, MJ1
Abou El Ella, DA; Aly, RM; El-Motwally, AM; Ibrahim, DA1

Other Studies

4 other study(ies) available for cl 387785 and erlotinib

ArticleYear
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
    Journal of medicinal chemistry, 2006, Feb-23, Volume: 49, Issue:4

    Topics: Alkynes; Amides; Aniline Compounds; Animals; Antineoplastic Agents; Cell Line; Dogs; ErbB Receptors; Haplorhini; Humans; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Pyrimidines; Quinazolines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-4; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2006
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-11, Volume: 104, Issue:50

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genotype; Humans; Neoplasms; Protein Kinase Inhibitors

2007
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
    Journal of medicinal chemistry, 2013, Sep-12, Volume: 56, Issue:17

    Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship

2013
Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
    European journal of medicinal chemistry, 2015, Sep-18, Volume: 102

    Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship

2015